Skip to content
Medical Health Aged Care

QPS Announces New Laboratory Services for Clinical Trials and Cell Therapy Development

QPS Holdings, LLC 3 mins read
NEWARK, Del.--BUSINESS WIRE--

QPS, a leading global contract research organization (CRO), is pleased to announce new laboratory services capabilities. The central laboratory, leukopak cell therapy facility, and enhanced PBMC capabilities will complement existing bioanalysis, translational medicine and peripheral blood mononuclear cell (PMBC) laboratories and extend the current QPS full-service global CRO offerings.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240626261072/en/

QPS Missouri, a division of QPS Holdings, LLC, a global Contract Research Organization. QPS Missouri conducts Phase I-IV clinical trials and houses central lab, safety lab, PBMC and cell production services in Springfield, Missouri. (Photo: Business Wire)

QPS Missouri, a division of QPS Holdings, LLC, a global Contract Research Organization. QPS Missouri conducts Phase I-IV clinical trials and houses central lab, safety lab, PBMC and cell production services in Springfield, Missouri. (Photo: Business Wire)

QPS now offers clinical trial sample analysis services and leukopak cell therapy products from its newly expanded clinical trials unit conveniently located in Springfield, Missouri. In addition, QPS has also expanded PBMC service offerings from its Miami, Florida location into its Springfield, Missouri laboratories. The new facilities are housed with an existing clinical (safety) laboratory, a modern self-contained pharmacy, and dedicated space to build and ship clinical trial kits.

The modern central laboratory for sample analysis complements the existing on-site safety laboratory, equipped with the most up-to-date technologies for chemistry, urinalysis, serology, coagulation, and hematology testing. These capabilities, designed to monitor subject safety during ongoing clinical trials, will remain as core services for QPS in-house clinical trials.

The new leukopak products collection and processing facility is designed to meet the exponential growing demand for blood products to support cell therapy research and QPS is ideally placed to provide this service. QPS Missouri has a database of over 35,000 potential study participants, who can be contacted as potential blood donors for leukopak products.

“There is significant unmet demand in this rapidly growing area of cell therapy products, which represents a tremendous opportunity for QPS. Over 3,000 cell and gene therapy programs are currently in progress representing a 20% increase over the past five years. These programs require leukopak products to move forward, and as a result this market is forecasted to grow by a CAGR of more than 8% over the next six years,” said Benjamin Chien, Chairman, President and CEO of QPS.

The enhanced PBMC services include a new PBMC processing lab at the Springfield location, complementing the existing lab at QPS Miami in Miami, Florida. This new lab will support a current unmet need for PBMC processing in the midwestern USA. PBMC sample analysis is a time-consuming process, typically required in vaccine trials, and it is best done in a lab adjacent to the clinical trial unit. QPS is uniquely positioned to offer this service.

“These new facilities, services and products extend our full service CRO capabilities, putting QPS in a position to offer clients comprehensive clinical research services in one location. The central lab, PBMC lab, and the leukopack facility complement and enhance our current 240 bed clinical trials unit, safety laboratory, modern self-contained pharmacy, and clinical trial kit production facility,” said Brendon Bourg, Vice President, Early Phase Clinical and Head of Administration at QPS Missouri.

ABOUT QPS HOLDINGS, LLC

QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, bioanalysis, preclinical and clinical drug development services. Since 1995, QPS has grown from a small bioanalysis shop into a full-service CRO with 1,100+ employees in the US, Europe, and Asia. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, clinical trials, and clinical research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, and turnkey laboratories and facilities. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance and trusted service to its valued customers. For more information, visit www.qps.com or email info@qps.com.


Contact details:

Gabrielle Pastore
1-302-635-4290
Gabrielle.Pastore@qps.com

Media

More from this category

  • LGBTQIA, Medical Health Aged Care
  • 05/07/2024
  • 14:01
Hepatitis Australia

Australia urged to accelerate action to end viral hepatitis

Friday, 5 July 2024 Australia has beenurged to accelerate action to eliminate viral hepatitis, with Health Minister Mark Butler MP addressing a renewed push to curb the epidemics. He spoke alongside Senators Louise Pratt and Dean Smith, Co-Chairs of Parliamentary Friends for ending HIV, STIs and Other Blood Borne Viruses, at Thursday’s federal parliamentary World Hepatitis Day event. Minister Butler highlighted the need for further action on prevention. “In partnership with affected communities, national peak bodies, peer and community organisations and the clinical multidisciplinary workforce, we are examining how to reduce the transmission of hepatitis C in the prison system,”…

  • Medical Health Aged Care
  • 05/07/2024
  • 02:10
King Faisal Specialist Hospital & Research Centre

KFSH&RC Achieves Remarkable 98% Survival Rate in 400 Robotic Cardiac Surgeries

RIYADH, Saudi Arabia, July 04, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSH&RC) has achieved a significant milestone in its Robotic Cardiac Surgery Program, which was initiated in February 2019. Within its first year, the program performed 105 cardiac procedures. As of today, 400 robotic cardiac surgeries have been performed with a remarkable 98% survival rate.KFSH&RC is leading a healthcare revolution by harnessing robotics to transform patient care and elevate surgical precision. Recognized as one of the top hospitals in robotic surgeries, it has cultivated a robust portfolio of expertise and ground-breaking achievements, solidifying its position…

  • Medical Health Aged Care
  • 04/07/2024
  • 17:36
The Australian Nursing and Midwifery Federation (ANMF)

ANMF condemns aged care providers for reclassifying lifestyle and allied health staff to meet mandated care minutes

The Australian Nursing and Midwifery Federation (ANMF) says the tactic being used by some aged care providers to reclassify lifestyle staff as Personal Care Assistants (PCAs) in a bid to meet their mandated care minutes responsibilities is undermining the Albanese Government’s ongoing reforms to fix the sector. Despite being funded to deliver landmark aged care reforms, reports have emerged of some aged care providers reclassifying lifestyle staff to PCAs, or cutting them altogether, to meet the current requirement of 200 minutes of care per resident per day. ANMF Federal Secretary Annie Butler said aged care providers must prioritise the well-being…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.